Netherlands Pharmaceuticals and Healthcare Industry Update Quarter 3 2012

  • May 2014
  • -
  • Business Monitor International
  • -
  • 115 pages

Includes 3 FREE quarterly updates
BMI View: While the Netherlands is a low risk industry from the point of view of multinational drugmakers, the country’s modest per capita expenditure on pharmaceuticals relative to other Western Europe countries remains an issue. A further challenge facing drugmakers is cost-containment, which can only intensify as the Netherlands enters a phase of slower economic growth.
Headline Expenditure Projections - Pharmaceuticals: Euros 6.70bn (US Dollar 9.31bn) in 2011 to Euros 6.54bn (US Dollar 8.44bn) in 2012; -2.4% decline in local currency terms and -9.4% decline in US dollar terms.
- Healthcare: Euros 63.32bn (US Dollar 88.02bn) in 2011 to Euros 65.09bn (US Dollar 83.96bn) in 2012; +2.8% growth in local currency terms and -4.60% growth in US dollar terms.
- Medical devices: Euros 11.41bn (US Dollar 15.86bn) in 2011 to Euros 11.77bn (US Dollar 15.18bn) in 2012; 3.2% growth in local currency terms and -4.2% in US dollar terms
- Business Environment Rating: The Netherlands’ composite score in our latest Pharmaceutical Risk/Reward Ratings (RRRs) matrix for Western Europe is unchanged from the previous quarter. The figure of 64.2 out of the maximum 100 ranks it seventh out of the 10 industry s in the matrix. Despite a developed healthcare industry, the Netherlands’ overall ranking continues to be propped up by its favourable risk variable, with the rewards negatively impacted by costcontainment, in combination with patent expirations.
Key Trends And Developments • In April 2012, a Chinese traditional medicine was authorized for sale in a European industry for the first time – Di'ao Xin Xue Kang, a well-known herbal medicine produced by the Chengdu based Di'ao Group, received industry ing authorization from the Medicines Evaluation Board of the Netherlands, making it the first Chinese traditional drug to be identified as a therapeutic medicine in the European Union.
BMI Economic View: The Dutch economy's exposure to the eurozone sovereign debt crisis continues to weigh heavily on economic activity and confidence. As a result, our weaker outlook for domestic demand means we now projection the economy to contract by 0.3% in 2012, from our previous 0.4% real Gross Domestic Product growth projection . Weak longer-term economic activity in the eurozone is also set to drag on the Netherland's growth trajectory and we projection economic growth to average a weak 1.1% to 2016..
BMI Political View: The stability of Netherlands’ Prime Minister Mark Rutte's minority government is likely to come under increased pressure in 2012, as the negotiations over Dutch involvement in eurozone bailout packages expose rifts between the coalition parties. In particular, with the far-right Party For Freedom gaining momentum, a coalition breakdown cannot be precluded, which could potentially stall some of the government’s fiscal austerity measures.

Table Of Contents

Executive Summary .... 5
Industry SWOT Analysis .... 6
Netherlands Pharmaceuticals And Healthcare Industry Environment and Risk Analysis ...... 6
Netherlands Political Environment and Risk Analysis ... 7
Netherlands Economic Environment and Risk Analysis . 7
Netherlands Business Environment SWOT... 8
Pharmaceutical Risk/Reward Ratings .. 9
Data : Western Europe Pharmaceuticals Risk/Reward Ratings, Q312 11
Rewards .... 11
Risks ... 12
The Netherlands - Industry Summary .. 13
Regulatory Regime ... 14
Regulatory Developments ..... 15
Intellectual Property Regime 15
Pricing And Reimbursement Regime ... 16

Industry Developments ... 19
Epidemiology ... 19
Healthcare Segment ... 20
Healthcare Funding 21
Health Insurance..... 21
Data : Key Points Of The Dutch Health Insurance Act, January 1 2006 .... 22
Healthcare Insurance Developments .. 23
Research And Development Segment ..... 24
Clinical Trials .. 27
Medical Devices Market ...... 27
Medical Devices Market Developments ... 27

Market Projection Scenario ... 29
Overall Industry Projection 29
Data : Pharmaceutical Sales Indicators from 2008 to 2016 30
Healthcare Industry Projection . 31
Data : Healthcare Expenditure Indicators from 2008 to 2016 ... 32
Data : Healthcare Governmental Indicators from 2008 to 2016 33
Data : Healthcare Private Indicators from 2008 to 2016 .... 33
Key Growth Factors - Macroeconomic ... 34
NETHERLANDS - ECONOMIC ACTIVITY ..... 37
Prescription Drug Industry Projection .... 38
Data : Prescription Drug Sales Indicators from 2008 to 2016 ... 38
Patented Drug Industry Projection .. 39
Data : Patented Drug Industry Indicators from 2008 to 2016 ...... 40
Generic Drug Industry Projection .. 41
Data : Generic Drug Sales Indicators from 2008 to 2016 ... 42
OTC Medicine Industry Projection .. 43
Data : OTC Medicine Sales Indicators from 2008 to 2016 .. 45
Pharmaceutical Trade Projection ... 46
Data : Exports and Imports Indicators from 2008 to 2016 .. 46
Medical Devices Industry Projection .... 48
Data : Medical Devices Sales Indicators from 2008 to 2016 ...... 49
Other Healthcare Data .. 50
Key Risks To BMI’s Projection Scenario ...... 50

Competition Overview .. 51
Pharmaceutical Market 51
Company Activities . 51
Pharmaceutical Wholesale Segment 53
Pharmaceutical Retail Segment ...... 54
Wholesale And Retail Segment Developments ...... 54
Company Profiles ..... 55
Local Manufacturers .... 55
DSM ... 55
Qiagen ...... 57
Pharming Group ..... 59
Multinational Manufacturers ..... 61
Merck and Co ..... 61
Pfizer.. 63
GlaxoSmithKline ..... 65
Sanofi . 67
Novartis .... 69
Demographic Data .... 70
NETHERLANDS - Population By Age Group .. 71
NETHERLANDS - Population By Age Group .. 71
NETHERLANDS - Key Population Ratios . 72
NETHERLANDS - Rural and Urban Population ..... 73
Glossary ...... 74
BMI Methodology ...... 76
How We Generate Our Pharmaceutical Market Projections .. 76
Pharmaceuticals Business Environment Ratings ..... 77
Risk/Reward Ratings Methodology ..... 77
Ratings Overview .... 77
Data : Pharmaceutical Business Environment Indicators ...... 78
Weighting .. 79
Data : Weighting Of Components 79
Sources ..... 79

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

  • $ 10 995
  • Industry report
  • May 2014
  • by Global Data

PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update Summary Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute ...

Antifungal Drugs : Technologies and Global Markets

Antifungal Drugs : Technologies and Global Markets

  • $ 6 650
  • Industry report
  • June 2014
  • by BCC Research

This report aims to determine the current status of the global human antifungal market and assess its growth potential over the five-year period from 2013 through 2018. It covers approved human therapeutics ...

DNA Vaccines: Technologies and Global Markets

DNA Vaccines: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • July 2014
  • by BCC Research

This BCC Research study determines the specific applications and global market demand for DNA vaccine products over a five-year period from 2014 to 2019. High growth and market potential segments of the ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.